KDM1A and breast carcinoma: To independently validate the effect of pharmacological inhibition of KDM1 on the growth of PELP1-driven (MCF-7-PELP1) and HER2-driven (MCF-7-HER2) breast cancer cells, we validated key findings using the recently developed KDM1-specific inhibitor NCL-1 [22].